Welcome to our dedicated page for Assembly Bioscie SEC filings (Ticker: ASMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Assembly Biosciences, Inc. (ASMB) SEC filings provide detailed insight into this clinical-stage biotechnology company’s operations, collaboration agreements and financial position. ASMB’s common stock is registered under Section 12(b) of the Exchange Act and trades on The Nasdaq Global Select Market, so the company submits current reports, registration statements and other documents to the U.S. Securities and Exchange Commission.
On this page, you can review Form 8-K filings in which Assembly Biosciences reports material events. Recent 8-Ks reference press releases announcing quarterly financial results, interim Phase 1b data for ABI-5366 in recurrent genital herpes, and topline Phase 1b results for ABI-4334 in chronic hepatitis B virus infection. Other 8-K filings describe an underwriting agreement for an underwritten, registered offering of common stock, pre-funded warrants and accompanying Class A and Class B warrants, as well as a securities purchase agreement with Gilead Sciences, Inc. for a private placement of common stock and warrants.
These filings outline key terms such as the number and type of securities issued, exercise prices and conditions for warrants, lock-up agreements, net proceeds to the company and intended use of funds for general corporate purposes. They also summarize aspects of the existing investor rights agreement with Gilead and the ownership limitations embedded in the warrants and pre-funded warrants.
For investors analyzing ASMB, the SEC filings complement the company’s press releases by providing formal descriptions of collaboration structures, financing transactions and clinical data disclosures. Stock Titan’s platform surfaces these documents alongside AI-powered summaries that explain the significance of each filing in accessible language, helping readers quickly understand items such as new offerings, private placements, collaboration milestones or clinical study updates.
In addition to 8-Ks, users can access other Assembly Biosciences filings through EDGAR, including annual and quarterly reports that discuss risk factors, collaboration revenue from Gilead, research and development expenses for HSV, HBV and HDV programs, and broader financial statements. Together, these regulatory documents form a primary source for evaluating ASMB’s business progress, capital structure and exposure to clinical and collaboration-related risks.
Assembly Biosciences PFO and PAO Jeanette M. Bjorkquist reported a mix of equity grants and related share sales. She received a grant of 6,500 restricted stock units (RSUs), scheduled to vest in four equal installments on March 29 of 2027, 2028, 2029, and 2030, assuming continuous service. Footnotes state that RSUs represent 65% of her annual equity grant and that the remaining 35% of RSUs is contingent on stockholder approval of an amendment to the company’s 2018 Stock Incentive Plan to increase authorized shares. On March 30, 2026, she sold a total of 328 common shares in open-market transactions at weighted average prices of $26.6502 and $27.49 per share to cover tax withholding obligations under a mandatory sell-to-cover rule, described as a non-discretionary transaction. Following these transactions, she directly holds 11,089 common shares.
Assembly Biosciences Chief Manufacturing Officer Nicole S. White received a grant of 26,000 restricted stock units (RSUs) and completed a small mandated share sale to cover taxes. The RSUs vest in four equal installments on March 29 of each year from 2027 through 2030, subject to continuous service. Footnotes state that 35% of the RSUs are contingent on stockholder approval of an amendment to increase shares authorized under the company’s 2018 Stock Incentive Plan. To satisfy tax withholding from RSU vesting, White sold a total of 197 common shares in open-market “sell-to-cover” transactions, described as required by a Compensation Committee administrative rule rather than discretionary trading. Following these transactions, she directly holds 37,477 common shares.
Assembly Biosciences Chief Medical Officer Anuj Gaggar received an equity grant tied to company stock. The Form 4 reports a grant of 26,000 shares underlying restricted stock units that were awarded at no cash cost to him.
The RSUs vest in four equal installments on March 29 of 2027, 2028, 2029 and 2030, assuming he remains in continuous service. The award represents 65% of his annual equity grant, while the remaining 35% is contingent on stockholder approval of an increase in shares authorized under the company’s 2018 stock incentive plan. After this grant, he directly holds 28,000 shares, including 2,000 shares previously acquired through the employee stock purchase plan.
Assembly Biosciences granted Chief Scientific Officer William E. Delaney IV 26,000 restricted stock units (RSUs) on March 29, 2026. The RSUs vest in four equal annual installments on March 29, 2027, March 29, 2028, March 29, 2029, and March 29, 2030, assuming continuous service on each date.
The RSUs represent 65% of his annual equity grant, while the remaining 35% is contingent on stockholder approval of an amendment to the company’s 2018 Stock Incentive Plan to increase authorized shares. After this grant, Delaney directly holds 45,642 common shares, including 2,909 shares acquired through the employee stock purchase plan on May 14, 2025.
Assembly Biosciences CEO and President Jason A. Okazaki received a grant of 94,250 restricted stock units (RSUs) of common stock. The RSUs vest in four approximately equal installments on March 29 of each year from 2027 through 2030, assuming continuous service on each vesting date. The RSUs represent 65% of his annual equity grant, while the remaining 35% of RSUs are contingent on stockholder approval of an amendment to the company’s Amended and Restated 2018 Stock Incentive Plan to increase shares authorized under the plan. Following this award, Okazaki beneficially owns 111,916 shares, including 2,909 shares previously acquired under the company’s Employee Stock Purchase Plan.
Assembly Biosciences, Inc. has adopted a new 2026 Corporate Bonus Plan, effective January 1, 2026, to motivate, retain, attract and reward employees using performance-based cash bonuses for results achieved between January 1 and December 31 each year.
Bonuses will be based on Company-wide “Corporate Objectives” and individual or team “Individual Objectives,” with weightings that vary by level, from 100% corporate for the CEO to 25% corporate and 75% individual for associate director and below. Target bonus opportunities range up to 75% of base salary for the CEO, 30%–55% for other executives and up to 28% for non-executives, with actual payouts ranging from 0 to 1.5 times the target. The Compensation Committee also increased CEO Jason A. Okazaki’s bonus target from 60% to 65% of base salary for fiscal 2026.
Assembly Biosciences, Inc. registered securities for an aggregate offering price of $400,000,000 under a shelf prospectus, and the related prospectus supplement covers up to $100,000,000 of common stock to be sold on an at-the-market basis.
The prospectus describes the types of securities that may be offered — common stock, preferred stock, debt securities, warrants, subscription rights and units — and states that specific terms will be provided in prospectus supplements. The supplement establishes an Open Market Sale Agreement with Jefferies LLC as sales agent for the $100,000,000 ATM program, and reports a last reported Nasdaq sale price of $27.52 per share as of March 18, 2026.
Assembly Biosciences, Inc. is a clinical-stage biotechnology company focused on next-generation antiviral drugs for serious viral diseases, including recurrent genital herpes, hepatitis B and D, and transplant-associated herpesviruses. Its pipeline features two long-acting helicase-primase inhibitors (5366 and 1179), an oral HDV entry inhibitor (6250), a next-generation HBV capsid assembly modulator (4334) and a broad-spectrum NNPI (7272).
In 2025 the company reported multiple positive Phase 1 data readouts across 5366, 1179, 4334 and 6250, generally showing strong antiviral activity, pharmacokinetics supporting convenient oral dosing and favorable safety profiles. Gilead Sciences exercised its option in December 2025 to exclusively license the HPI program, paying $35 million and taking over global development and commercialization, while Assembly remains eligible for up to $330 million in milestones plus tiered royalties and may later elect a 40% U.S. profit-share.
Assembly retains full control of 4334 after Gilead declined its option in March 2026 and is seeking a partner before advancing that HBV program. For HDV, Phase 2 initiation of 6250 is targeted for the fourth quarter of 2026. As of March 13, 2026, Assembly had 15,862,705 shares of common stock outstanding, and the aggregate market value of non-affiliate voting stock was $97.8 million as of June 30, 2025.
Assembly Biosciences reported sharply improved 2025 results, driven by its virology collaboration with Gilead. Collaboration revenue rose to $72.3M from $28.5M, while net loss narrowed to $6.1M, or $0.55 per share, from $40.2M in 2024.
Cash, cash equivalents and marketable securities increased to $248.1M as of December 31, 2025, supporting operations into 2028. The company received a net $35M option fee as Gilead licensed its helicase-primase inhibitor program, though Gilead declined its option on HBV candidate ABI‑4334. Assembly plans a potential U.S. cost-profit share election on the herpes program by mid‑2026 and aims to start Phase 2 for HDV candidate ABI‑6250 by the end of 2026.